The Histamine H4 Receptor pipeline drugs market research report outlays comprehensive information on the Histamine H4 Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Histamine H4 Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Dermatology, Ear Nose Throat Disorders, Central Nervous System, and Gastrointestinal which include the indications Atopic Dermatitis (Atopic Eczema), Chronic Urticaria Or Hives, Hearing Disorders, Acute Sensorineural Hearing Loss, Post-Operative Pain, Peripheral Neuropathic Pain, and Eosinophilic Esophagitis. It also reviews key players involved in Histamine H4 Receptor targeted therapeutics development with respective active and dormant or discontinued products.

The Histamine H4 Receptor pipeline targets constitutes close to seven molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 1, 2, 2, and 2 respectively.

Histamine H4 Receptor overview

The histamine H4 receptor is a member of the G protein-coupled receptor super family. H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function.

For a complete picture of Histamine H4 Receptor’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.